Conducting a clinical trial on amnion lyophilized product in improving complications after laser
Phase 1
Recruiting
- Conditions
- Skin aging.Atrophic disorder of skinL90.9
- Registration Number
- IRCT20200127046282N45
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Age between 30-60
Having middle wrinkles in face region
Exclusion Criteria
Pregnancy and breastfeeding
History of cancer
Patients with a new history of gel and Botox injections
People with Mental Disorders
Active infection in the face
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie amnion lyophilized allograft effects on skin aging and atrophy?
How does amnion lyophilized allograft compare to standard-of-care treatments for L90.9 skin atrophy post-laser?
Are there specific biomarkers that predict response to amnion allograft in fractional CO2 laser complications?
What adverse events are associated with amnion lyophilized allograft in phase I dermatological trials?
What combination therapies show potential with amnion allograft for improving skin aging outcomes?